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Single-stranded oligodeoxynucleotides (ODN), containing nonmethylated cytosine–guanine motifs (CpG
ODN), are recognized by the innate immune system as ‘‘danger signals.’’ CpG ODN are efficacious immu-
nomodulators but require phosphorothioate (PT) or other backbone modifications for metabolic stability, which
cause toxicities in mice and primates. We therefore designed a covalently closed DNA molecule (dSLIM)
where two single-stranded loops containing CG motifs are connected through a double-stranded stem in the
absence of any nonnatural DNA component. The most promising immunomodulator, MGN1703, comprises two
loops of 30 nucleotides containing three CG motifs each, and a connecting stem stem of 28 base pairs. MGN1703
stimulates cytokine secretion [interferon (IFN)-a, IFN-g, interleukin (IL)-12, IL-6, and IL-2] and activates im-
mune cells by increased expression of CD80, CD40, human leukocyte antigen (HLA)-DR and ICAM-1. Efficacy
of immunomodulation strictly depends on the descriptive dumbbell shape and size of the molecule. Variations in
stem length and loop size lead to reduced potency of the respective members of the dSLIM class. In a
representative mouse model, toxicities from injections of high amounts of a CpG ODN-PT and of MGN1703 were
evaluated. The CpG ODN-PT group showed severe organ damage, whereas no such or other pathologies were
found in the MGN1703 group. Oncological clinical trials of MGN1703 already confirmed our design.
Introduction
Oligodeoxynucleotides containing nonmethylatedcytosine moieties within cytosine–guanine sequence
motifs (CpG ODN) are potent immunomodulators [1,2].
Nonmethylated CG sequence motifs resemble bacterial, certain
viral, and also mammalian mitochondrial DNA in terms of this
signature [1–5] and are therefore recognized as ‘‘danger sig-
nals’’ if such DNA is detected in nonappropriate intracellular
environments by the innate immune system. Nonmethylated
CG motifs either signal infection as pathogen-associated mo-
lecular patterns or are interpreted as the molecular signature of
decaying mammalian cells, then termed damage associated
molecular patterns. CpG ODN bind and activate Toll-like
receptor 9 (TLR-9), which in the human immune system is
located in the endoplasmic reticulum of plasmacytoid dendritic
cells (pDC) and B cells [6]. TLR-9 activation subsequently
triggers a signaling cascade involving MyD88, IRAK, and
TRAF-6 leading to the activation of NF–kB and IRF7 pathways
[1,2,7–9]. This results in the production of proinflammatory
cytokines and the type 1 interferon response, leading to the
activation and maturation of dendritic cells (Langerhans cells,
pDC, myeloid dendritic cells mDC), the proliferation of B cells,
and to the proliferation and activation of innate effector cells
[e.g., natural killer (NK) cells and invariant NKT cells] among
others. Eventually, through the bridging function of mature,
activated DC the adaptive immune system responds [10–12].
CpG ODN can be classified into three separate classes with
different structural characteristics and differentially enhanc-
ing antigen-specific humoral and cellular immune responses:
class A are strong inducers of interferon (IFN)-alpha from
pDC but very poor B cell activators and class B are potent
stimulators of B cell proliferation with poor induction of pDC
IFN-alpha secretion, while class-C CpG ODN exhibit mod-
erate properties from both class A and class B [13,14].
Being stimulators of the innate and adaptive immune
system, CpG ODN have shown promising therapeutic po-
tential as vaccine adjuvants [15–18], as mediators of pro-
tective immunity against certain infections [19,20], and as
immune therapeutics against cancer [21–23].
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The most extensively studied single-stranded CpG ODN has
been the Class B, PF-3512676 (ProMune, CpG-7909 or
ODN2006) [24]. Two phase 3 trials of PF-3512676 adminis-
tered in combination with standard chemotherapy regimens as
first-line treatment in advanced non-small-cell lung cancer have
not shown improvement in median overall or progression-free
survival [25,26]. However, patients receiving PF-3512676 ex-
hibited a higher proportion of adverse events ‡ grade 3 in both
studies. Due to the lack of significantly improved efficacy and
increased toxicity resulting in an unfavorable risk–benefit pro-
file seen with PF-3512676, both trials were terminated early.
Phosphorothioate (PT) modifications of the DNA backbone,
usually introduced to enhance stability against degradation
in vitro and in vivo [27–29] rendered the resulting ODN-PT
much more potent in stimulation of B-cell proliferation than the
corresponding ODN with a natural phosphorodiester backbone
(ODN-PO) [10,30]. However, PT-modifications result in sev-
eral toxic side effects that may—at least in part—account for
the above-mentioned clinical failures: CpG ODN-PT lead to a
prolongation of the blood clotting time via inhibition of the
intrinsic tenase complex [31–33]. CpG ODN-PT may affect
cell signaling by nonspecific binding to various proteins (i.e.,
transcription factors) [34]. In rhesus monkeys CpG ODN-PT
lead to acute toxicities via complement activation [35,36], an
effect that also appeared after treatment of normal donor serum
with CpG ODN-PT [33]. In rats, CpG ODN-PT were stronger
promoters of thrombocytopenia, anemia, or neutropenia than
the corresponding CpG ODN-PO [37]; and in mice, the PT-
backbone showed a synergistic effect in the induction of
arthritis [38]. Most importantly, however, CpG ODN-PT ac-
counted for dramatic destruction and reduced functionality of
lymphoid organs in mice [39].
PT or other modifications to protect against exonucleolytic
degradation can be avoided if DNA molecules lack open ends
like in covalently-closed dumbbell-like structures [40–42].
By this general design principle, we developed a new family
of TLR-9 agonists by the name of double stem-loop immu-
nomodulators (dSLIM). dSLIM are synthesized by ligation
of two identical DNA molecules with stable stem-loop
structures, resulting in covalently closed molecules of natural
DNA (i.e., with a 3¢, 5¢-phosphorodiester backbone), which
descriptively form a dumbbell-like structure. The immuno-
modulatory nonmethylated CG motifs are placed in the
single-stranded loops, double-stranded stem, or in both.
Here, we present the molecular design path to MGN1703
from other molecules of the dSLIM family. To assay the re-
spective design variants for activation of the TLR-9 pathway,
we first employed specific cell lines of different origin as a
model system and later confirmed our data in human peripheral
blood mononuclear cells (PBMC) from healthy donors. The
cell line systems allowed for the detection of subtle differences
in TLR-9 activation that would have been lost in PBMC assays
due to the individual variability of PBMC from donors. On the
other, only in PBMC most aspects of innate and adaptive
immune activation by dSLIM molecules could be assessed.
Finally, toxicological studies in rodents are reported.
Materials and Methods
TLR-9 agonists for immunomodulation
MGN1703 and other molecules of the dSLIM family were
generated as described [43,44]. The endotoxin content of all
nucleotide molecules was determined by an endpoint limulus
amebocyte lysate test to be below 10 EU/mg DNA. If not
denoted otherwise, a final concentration of 1mM was used for
each molecule.
To evaluate the effect of backbone modifications or
substitution of CG motifs, we designed several variations (Mod-1
to Mod-9) of the standard MGN1703, a dumbbell-shaped
molecule with two single-stranded loops of 30 nucleotides
each containing three nonmethylated CG motifs and a 28-bp
double-stranded stem. CG motifs were replaced by TG motifs
to investigate CG dependence in control molecules (noCpG
ODN, noCG-MGN1703).
Cells
RPMI-8226, Jurkat, MOLT-3, U937, NK-92, and YT cells
were obtained from the Deutsche Sammlung von Mikroor-
ganismen und Zellkulturen GmbH (Braunschweig, Ger-
many) and were cultured as recommended. Cells were
stimulated with 1mM of respective molecules of the dSLIM
family or CpG ODN for 48 hours unless noted otherwise.
Human peripheral mononuclear blood cells were isolated
from peripheral blood of normal volunteers via Ficoll tech-
nique as described previously [45,46].
Flow cytometry
Cells were stimulated with MGN1703 and other molecules
of the dSLIM family and flow cytometry was performed as
described [43,47]. Briefly, 48 hours after stimulation, cells
were washed with phosphate-buffered saline (PBS) and 1· 106
cells were resuspended and stained with anti-CD80-fluorescein
isothiocyanate (FITC), anti-CD86-phycoerythrin (PE), anti-
CD40-FITC, anti-CD69-PE, anti-CD54-FITC, anti-human
leukocyte antigen DR (HLA-DR)-PE, anti-CD28-FITC, anti-
cytotoxic T-lymphocyte-associated protein 4 (CTLA4)-PE (all
from Becton Dickinson), or anti-human leukocyte antigen
ABC (HLA-ABC)-PE (Dako Cytomation) and incubated for
30 minutes. The cells were subsequently washed with PBS
[Dulbecco’s PBS 0.0095 M (PO4) w/o calcium and magne-
sium, Lonza]. The isotypes immunoglobin G (IgG)1-FITC,
IgG2a-FITC, IgG2a-PE, and IgG1-PE (all from Becton
Dickinson) were always used as negative controls. Necrotic
cells were detected by propidium iodide staining and excluded
from analysis. The measurements were carried out using a
FACScalibur flow cytometer (Becton Dickinson) and analyzed
via CellQuest and WINMDI2.8 Software.
Enzyme-linked immuno assay
Cytokine enzyme-linked immuno assays were performed
with supernatants of 106 cells/mL that had been cultured for
48 hours according to the manufacturer’s instruction [IFN-g,
interleukin (IL)-12p40, IL-6, and IFN-a, R&D Systems].
Stability assay
A stability study according to International Conference on
Harmonisation over 36 months at –20C has been performed
for MGN1703. Identity, purity, and content were analyzed via
photometric determination, high-performance liquid chroma-
tography (HPLC), and gel electrophoresis. This stability data
fulfilled all set specifications.
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Toxicology studies in mice
Mice studies were performed as described previously [39].
Briefly, groups consisting of 6-week-old, female C57BL6
mice were administered PBS (control), MGN1703, and
ODN1826 intraperitoneally at different doses (in 100mL
volume) once daily for 7 days. At the end, all mice were
sacrificed and organs were weighed immediately. Subse-
quently, liver and spleen were stored in 4% paraformaldehyde
at room temperature. Paraformaldehyde-fixed sections of
spleen and liver were stained with hematoxilin/eosin for his-
tological report. Analysis was performed as a double-blind
evaluation. An analysis of variance test was used for statistical
analysis of organ weights. Mice studies were performed in
accredited animal facilities at Direccio´n General de Agri-
cultura, Comunidad de Madrid (EX–023-USC) following the
respective standard operating procedures, directives, and local
laws: [European Directives 2003/65/EC/86/609/CEE; Span-
ish Law RD 223/1988; Humane Endpoints Guidance Docu-
ment of the Organisation for Economic Co-operation and
Development ENV/JM/MONO(2000)7; and Federation of
Laboratory Animal Science Associations guidelines].
Results
MGN1703, a member of the dSLIM family
Commonly used PT-modified CpG ODN are known for
clinically relevant side effects, such as unspecific protein
binding, prolongation of blood clotting, and acute toxicities
[31–39]. As a radical alternative we designed a family of
double stem-loop immunomodulatory DNA molecules
(dSLIM) with natural phosphorodiester (PO) DNA back-
bones lacking open 3¢ and 5¢ ends. Such covalently closed
constructs can be drawn as a dumbbell-like shape, where two
single-stranded loops are connected through a double-stranded
stem. One member of the dSLIM family, MGN1703, consists
of a stem of 28 base pairs (bp) and two loops of 30 nucleotides
(nt) with identical sequences, containing three nonmethylated
CG motifs each (Fig. 1A). The MGN1703 sequence was
confirmed by standard sequencing of the primary ODN be-
fore the ligation step. Integrity of the covalently closed
structure was assayed via exonuclease digestion and subse-
quent gel electrophoresis or HPLC. MGN1703, when stored
at a temperature of - 20C, was stable for a minimum of 36
months (data not shown).
MGN1703 increases expression of immunological
surface markers and cytokine secretion
CpG ODN are known to stimulate expression of immu-
nological markers on the cell surface and production of cy-
tokines in vitro [1,2]. We investigated the effect of MGN1703
on various cell lines representing components of innate and
adaptive immune responses, like B-lineage cells (RPMI-
8226), T-lineage cells ( Jurkat, MOLT-3), monocytes (U937),
and NK cells (NK-92, YT). Analyzing surface expression of
FIG. 1. Immunomodulatory potential of MGN1703. (A) Schematic draw of a member of the double stem loop immu-
nomodulators family (MGN1703) with cytosine–guanine (CG) motifs in black. ds, double strand; ss, single strand (B)
Representative flow cytometric analysis of RPMI-8226 cells incubated with or without MGN1703 for 48 hours. FSC,
forward scatter. (C) Interleukin (IL)-12p40 enzyme-linked immune assay (ELISA) of supernatant from RPMI-8226 cells.
(D) Interferon-gamma (IFN-g) ELISA of supernatant from natural killer (NK)-92 cells. (E, F) Example of a concentration-
dependent stimulation of ICAM-1 and human leukocyte antigen (HLA)-DR surface expression on RPMI-8226 analyzed via
flow cytometry. (G, H) Concentration-dependent activation of IFN-a and IL-6 cytokine production from healthy donor
peripheral blood mononuclear cell (PBMC) analyzed via ELISA. Each line represents one donor.
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immunologically relevant molecules CD80/B7-1, CD86/B7-
2, CD40, CD40L/CD154, CD28, CTLA-4/CD152, HLA-DR,
ICAM-1/CD54 and CD69 by flow cytometry, we observed
no direct effect of MGN1703 on T-lineage cells, NK cells or
monocytes. However, B-lineage RPMI-8226 cells showed
an increased surface expression of CD80/B7-1, CD40
(Supplementary Fig. S1; Supplementary Data are available
online at www.liebertpub.com/nat), HLA-DR (Fig. 1B),
and ICAM-1/CD54. Regarding cytokine secretion, only a
moderate stimulation of IL-12 (p40 subunit) production
from RPMI-8226 (Fig. 1C) and IFN-g secretion from
NK-92 cells (Fig. 1D) was found after incubation with
MGN1703, confirming that signaling and interaction be-
tween different cell types are required to generate the typ-
ical downstream effects of TLR-9 activation by MGN1703.
In keeping with this, human PBMC, when incubated with
MGN1703, induced production of a specific cytokine pat-
tern consisting of T helper cell 1 (TH1) cytokines IFN-a,
IFN-g, and IL-12p40, and the proinflammatory cytokine IL-
6 (Table 1). All these immunomodulatory effects were
clearly dose dependent (Fig. 1E–H).
Immunomodulatory potential of MGN1703 is strictly
structure dependent
Some reports described the requirement of nucleic acid
secondary structure or the buildup of higher molecular
complexes as a prerequisite of immunological efficacy
[48,49]. Therefore, we designed variants of stem-loop con-
structs differing in number and distribution of CG motifs,
stem and loop size, and number of loops and evaluated
their modulatory potential. Besides MGN1703, these were a
single-loop stem construct (Mod-1), a double-loop stem con-
struct with CG motifs in only one loop (Mod-2), and another
double-loop stem construct with CG motifs in its stem (Mod-
3) (Fig. 2A). All molecules contained the same immuno-
modulatory sequence, a stretch of at least 20 nucleotides
containing 3 CG motifs. Regarding expression of surface
Table 1. Stimulation of Human Peripheral Blood Mononuclear Cells with MGN1703
IFN-a [pg/mL] IL-6 [pg/mL] IFN-c [pg/mL] IL-12p40 [pg/mL] IL-2 [pg/mL] TNFa [pg/mL]
Control 4 < 25a < 15a < 25a 46 – 25 16 – 1
MGN1703 1712– 342 567 – 456 116 – 40 117– 25 101 – 36 52 – 3
Human peripheral blood mononuclear cells were incubated with 1 mM MGN1703 for 48 hours and cytokine levels analyzed via enzyme-
linked immune assay.
Results presented as mean values – standard error.
aBelow the detection level of the enzyme-linked immune assay.
IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.
FIG. 2. Influence of structure and CG motif availability on function of MGN1703. (A) Schematic drawing of MGN1703
and modified molecules with CG motifs in black. (B, C) Stimulation of CD80/B7-1 (B) and HLA-DR (C) surface
expression on RPMI-8226 cells analyzed via flow cytometry. SSC, side scatter. (D, E) Activation of normal donor PBMC to
produce IFN-a (D) and IL-6 (E), which was analyzed via ELISA. Dotted lines connect the samples from one donor. (F)
Activation of IL-12p40 production by murine spleen cells as analyzed by ELISA.
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molecules CD80/B7-1 and HLA-DR, a change in structure
and number of CG motifs reduced the activation potential
compared with MGN1703 (Fig. 2B, C).
In keeping with this, MGN1703 also generated the highest
stimulation of cytokine production compared with the mole-
cules when IFN-a and IL-6 production from healthy donor
PBMC and IL-12p40 from murine spleen cells were analyzed
(Fig. 2D–F). To investigate the importance of structure in
more detail, we generated further variations of MGN1703
with increased (from 28 bp to 56 bp and 88 bp) or decreased
stem size (from 28 bp to 22 bp and 16 bp). Accordingly, we
decreased the MGN1703 loop size (from 30 nt to 24 nt and 20
nt) while maintaining the 20-nt immunomodulatory sequence
of that encompasses the CG motifs. The resulting molecules
Mod-4 to Mod-9 are shown in Figure 3A. Notably, these
structure variations of MGN1703 clearly diminished its im-
munomodulatory potential, as shown by IFN-a, IFN-g, and
IL-6 production from PBMC (Fig. 3B–D). Using even
smaller constructs with only one CG motif per loop or two
CG motifs in the stem confirmed the necessity of CG motifs
in both loops but not in the stem for a high potency (Sup-
plementary Fig. S2). These data clearly demonstrate the
importance of a certain structure, size, CG motif content, and
positioning of CG motifs on the efficacy of MGN1703 in both
human and murine cells.
MGN1703 does not induce toxicities in rodents
Heikenwalder et al. showed that a CpG ODN-PT resulted
in significant toxic effects in mice (i.e., dramatically reduced
functionality and definition of lymphoid organs) [39]. To
confirm the safety of MGN1703, we used a similar mouse
model and successive injections of 2.5 mg or 60mg of DNA-
based immunomodulators, comparing MGN1703 consisting
of natural DNA entirely with ODN1826 as a CpG ODN with
a PT-modified backbone. After seven daily intraperitoneal
injections of MGN1703, we did not detect any increase of
liver, spleen, or lymph node weight compared with PBS in-
jection, neither with low dose (2.5 mg) nor high dose (60mg)
of MGN1703 (Fig. 4A, B).
In contrast, ODN1826 led to significant weight increase
of these organs—with the 2.5 mg dose and even more with
60 mg of the CpG ODN-PT (Fig. 4A, B). This repeated the
experiments with and confirmed the high toxicity of the CpG
FIG. 3. Influence of size on function of MGN1703. (A) Schematic drawings of MGN1703 and derived molecules with CG
motifs shown in black (Mod-4 to Mod-9). Numbers of nucleotides are denoted in the loops; numbers of base pairs are
shown on top of the stem. (B–D) Activation of healthy donor PBMC to produce IFN-g (B), IL-6 (C), and IFN-a (D) which
was analyzed via ELISA. Dotted lines connect the samples from one donor.
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ODN described in the paper by Heikenwalder et al. [39]. The
absence of toxicity after MGN1703 injections and the drastic
toxicity from ODN1826 injections was not due to the dif-
ference in molecular weight (MGN1703 >ODN1826) and
the resulting higher number of ODN1826 molecules com-
pared with MGN1703 at equal masses of injected molecules.
As shown in Figure 4C, the highly significant differences
were also observed if equimolar amounts of the respective
molecules were injected, though both MGN1703 and
ODN1826 were able to raise IL-12p40 levels in mice sera
(Fig. 4C). Histopathological analyses of liver and spleen
tissues confirmed the differences as well (Figs. 5, 6). While
MGN1703 had only a slight effect on histopathology,
ODN1826 resulted in vastly increased liver damage from
inflammatory reaction and hepatocyte necrosis (regarding
number and size of lesions). Damage of spleen produced
similar impressive evidence, such as red pulp hyperplasia
with intense extramedullary hematopoiesis and alteration of
the white pulp (Table 2). The organ alterations caused by
ODN1826 administration are not the equivalent of a normal
immune response but do indicate toxic effects on the tissues
analyzed.
This led us to evaluate the safety of MGN1703 under the
defined conditions of good laboratory practice (GLP). We
performed acute toxicity studies in rats by single intravenous
injections of 0.8, 2.7, or 10.4 mg/kg of MGN1703 or subcu-
taneous injections 0.8, 3.1, or 15.4 mg/kg. None of these in-
jections resulted in any toxic effect, neither regarding
mortality, clinical signs (i.e., changes in skin, fur, eyes, mu-
cous membranes, occurrence of secretions and excretions,
autonomic activity, presence of abnormal movements, etc.)
nor significant alterations after macroscopic evaluation of the
external surface of the body and necropsy of organs (kidneys,
heart, spleen, liver, peritoneum, mesenteric lymph nodes, and
thymus) (data not shown).
Discussion
Backbone-modified ODN, especially CpG ODN-PT, have
been evaluated in various clinical trials as promising thera-
peutics or adjuvants in the treatment of allergies, certain in-
fections, and cancer [50,51]. However, they almost all failed
in pivotal trials, probably due to a far too narrow therapeutic
window. Safety concerns had earlier been raised from results
of in vivo mice experiments, where commonly used CpG
ODN-PT caused severe side effects such as destruction of
lymphoid organs and hepatosplenomegaly [39].
As shown here, we have developed a new family of potent
TLR-9 agonist—the dSLIM family of immunomodula-
tors, with its most prominent member being MGN1703—
consisting of only natural DNA to avoid toxicities and clinical
side effects most likely being caused by the PT modifications,
while maintaining specific immune activation properties.
Protection against degradation by nucleases is achieved by the
covalently closed molecular structure of MGN1703. We have
shown that the immunomodulatory effect of MGN1703 is
clearly dependent on its structure and the CG motif content
as well. This fact is corroborated by experiments, where
MGN1703 control molecules with no CG motifs had no rele-
vant immunomodulatory effect (Supplementary Fig. S3).
Among the known side effects of CpG ODN-PT is the
prolongation of blood clotting time [31]. As expected, the
natural (PO) DNA of MGN1703 did not prolong activated
partial thromboplastin time in peripheral blood samples
from normal donors, whereas the CpG ODN-PT clearly did
(Supplementary Fig. S4).
Selective CpG ODN have been characterized for optimal
stimulation of murine, primate, or human cells [52,53]. Un-
like PF-3512676 (ProMune, CpG-7909 or ODN2006), which
was the TLR-9 agonist most often used in human clinical
trials, MGN1703 overcomes such ‘‘species specificity,’’
FIG. 4. Effect of MGN1703 and phosphorothioate (PT)-
based oligodeoxynucleotide 1826 (ODN1826) on liver and
spleen size from mice and cytokine production in vivo. (A)
Absolute liver weight after seven daily injections of each
60 mg (left) and 2.5 mg (right) of MGN1703 (gray bars) or
ODN1826 (black bars). (B) Relative spleen weight after
seven daily injections of equal mass (60mg, left) and equi-
molar (1.7 nmol, right) amounts of MGN1703 (gray bars) or
ODN1826 (black bars). (C) In vivo serum levels of IL-
12p40 after seven daily injections of equal mass (60mg, left)
and equimolar (1.7 nmol, right) amounts of MGN1703 (gray
bars) or ODN1826 (black bars). Statistically significant
differences to the phosphate-buffered saline (PBS) control
are denoted with stars (**p < 0.01, ***p < 0.001).
MGN1703, A POTENT AND SAFE TLR-9 AGONIST 135
FIG. 5. Histopathology of the liv-
er after seven daily injections of
MGN1703 or PT-based ODN1826
into mice. (A) Injection of PBS
(control); (B) 7·2.5mg MGN1703;
(C) 7·2.5mg ODN1826; (D) 7·
60mg MGN1703; (E, F) 7·60mg
ODN1826. (A, B, D) Minor inflam-
matory reaction (triangles) predomi-
nantly associated to the presence
of macrophages and neutrophils. (C)
Multiple inflammatory areas with
necrotic hepatocytes (black arrows)
and incipient necrosis (red arrows):
intense presence of macrophages and
some neutrophils. (E, F) Multiple
inflammatory areas with incipient ne-
crosis of hepatocytes (black arrows):
intense eosinophilic response in the
cytoplasm, nuclear pyknosis, and
karyolysis. Representative pictures
are shown.
FIG. 6. Histopathology of the
spleen after seven daily injections of
MGN1703 or PT-based ODN1826
into mice. (A) Injection of PBS
(control); (B) 7·2.5mg MGN1703;
(C) 7·2.5mg ODN1826; (D) 7·
60mg MGN1703; (E, F) 7·
ODN1826. (A, B, D–F) White pulp
shows a normal structure, including
germinal centers (triangles). (C)
Normal lymphoid cells; no evidence
of follicular germinal centers. (E)
Red pulp hyperplasia, showing mac-
rophages, myelopoietic, and mega-
caryocytic cells with extensive
histiocytic cells. (F) Red pulp: lym-
phoplasmocytic and hematopoietic
cells with extensive histiocytic cells.
Representative pictures are shown.
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facilitating the translation of mice experimental results into
clinical trials. The efficacy of MGN1703, with its non-
modified DNA backbone, in both murine and human cells is
perfectly in line with the results of Roberts and colleagues,
who have shown that the species specificity of active CpG
ODN is restricted to only CpG ODN-PT [54]. A synthetic
CpG ODN analogue in which the deoxycytidine was re-
placed by a bicyclic heterobase also overcomes species
specificity. The equivalent molecule but with a PT-modified
backbone was rendered toxic and led to spleen enlargement
in mice [55].
Secondary structure of MGN1703 as defined by size of
double-stranded stem, size and number of loops, and dis-
tribution of the CG motifs is crucial for an optimal im-
munomodulatory potential. A possible explanation why
stem-located CG motifs have significantly reduced immu-
nomodulatory efficacy compared with CG motifs positioned
in the loop can be derived from the work of Rutz et al. [49].
Binding studies suggest interaction of single-stranded, but
not of double-stranded DNA with TLR-9 in a pH-dependent
manner. Naturally occurring double-stranded DNA of bac-
teria is hypothesized to require the acidic conditions in the
endosomes for degradation into multiple single-stranded
CG motif fragments for subsequent signal transduction by
TLR-9. In case of MGN1703, the CG motif located in the
single-stranded loop is assessable and may directly interact
with TLR-9, whereas in case of the modified molecule Mod-3
degradation of the double-stranded stem containing the CG
motifs may be required, thus leading to decreased efficacy in
TLR-9 activation.
There are discussions about the interaction of CG motif
containing molecules with TLR-9 or with another molecule:
On one hand, direct binding of single-stranded non-
methylated CpG ODN-PO to TLR-9 in a sequence- and pH-
dependent manner has been demonstrated, and a possible
DNA binding region within TLR-9 has been identified [49].
However, direct binding of PT ODN to TLR-9 occurred in-
dependent of CG motifs and was attributed to nonspecific
binding of the PT backbone to proteins. Haas et al. showed
that the sugar moieties of the DNA backbone determined
recognition by TLR-9 [4]. PO-2¢-deoxyribose homopolymers
were found to bind and mediate activation of TLR-9. In
contrast, PT-modified polymers bound TLR-9 100-fold more
strongly, but competitively inhibited ligand-induced TLR-9
stimulation. CG motifs were able to convert this inhibition
into strong TLR-9 activation. Accordingly, we hypothesize
that MGN1703 containing only natural PO bonds in its DNA
backbone mediates TLR-9 activation via its sugar backbone
with CG motifs enhancing its immunomodulatory effects.
The requirement for TLR-9 in MGN1703-induced im-
munomodulation is corroborated by application of chloroquine,
an inhibitor of endosomal acidification – a process necessary
for TLR-9 signaling [49,56]. Chloroquine completely abro-
gated the induction of IFN-gamma-inducible protein 10 in
MGN1703-stimulated PBMC and strongly diminished the
percentage of activated enhanced green fluorescent protein–
positive RAW264.7 reporter cells (transfected with human
NF–kB responsive endothelial leukocyte adhesion molecule
(ELAM) promoter–green fluorescent protein construct: ELAM
9) (Supplementary Fig. S5) [57]. Another indication for the
importance of TLR-9 in the immunomodulation by MGN1703
is the inhibition of the stimulation by ODN with no CG motif
(control molecule)—most likely due to competition at the
recognition sites of TLR-9. Both, stimulation of surface marker
expression as well as cytokine production were clearly reduced
when MGN1703 and noCpG ODN were combined for incu-
bation of PBMC or ELAM 9 cells (Supplementary Fig. S3 and
Fig. S6). Furthermore, MGN1703 activated enriched pDC but
not mDC to produce IFN-a (data not shown); pDC are known
to be TLR-9 positive, whereas mDC do not express TLR-9.
TLR-9 has been found to be constitutively expressed as an
inactive dimer and to change into an active confirmation upon
binding of CpG DNA in the endosome so that the cytoplas-
mic TLR-9 Toll–interleukin 1 receptor signaling domains
come in close proximity, enabling signal transduction by
recruitment of MyD88 [58]. The specific secondary structure
requirements for the optimally active MGN1703 molecule
might thus result from a better induction of the conforma-
tional change of TLR-9.
On the other hand, a third molecule might hold the two
TLR-9 receptors together and could also be involved in TLR-
9 activation by holding two TLR-9 molecules together. A
possible candidate is heat shock protein 90 (hsp90), which
directly binds to CG motifs in CpG ODN-PO [59]. The im-
portance of hsp90 for CpG ODN-PO–mediated signal
transduction is also suggested by Okuya et al., who recently
showed that hsp90 converted inert self-DNA or mainly CpG
ODN-PO into potent triggers of IFN-a secretion [60]. Thus,
the importance of secondary structure of MGN1703 might
also result from different affinity to hsp90, or yet another
unknown molecule involved in CG motif recognition and
cellular or endosomal uptake or translocation.
Table 2. Histopathological Evaluation of Liver and Spleen from Mice After Seven Injections











Necrotic hepatocytes ( + ) ( + ) + + + ( + ) + +
Inflammtory reaction ( + ) ( + ) + + + ( + ) + +
Spleen damage
Uniform lymphoid population – ( + ) + – +
Diffuse lymphoid activation – – + – +
White pulp hyperplasia – – – – ( + )
Red pulp hyperplasia – – + + + – –
( + )/+ / + + / + + + , degree of changes in relation to ODN1826 [60mg/day] as group with most severe changes; – not observed.
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In our mice experiments, the dose of MGN1703 for the
toxicological studies was 3 mg/kg and 0.1 mg/kg body
weight, adopted from Heikenwalder et al. [39]. Even though
the dose of 3 mg/kg is considerably higher than the amount
actually used of MGN1703 or CpG ODN in human clinical
trials, the dose of 0.1mg/kg is at the lower end of the general
human therapeutic range (0.1–0.6 mg/kg). Still, the low
dose of PT-containing ODN1826 showed considerable
toxicity in mice, whereas this was not observed with
MGN1703. Together with the results of acute toxicity
studies from GLP safety, we conclude that an application of
MGN1703 should be safe, while exhibiting great immu-
nomodulatory potential.
Consisting only of natural DNA, MGN1703 could better
mimic the immunomodulatory effects of bacterial DNA,
though avoiding the unwanted side effects of CpG ODN-PT.
Thus, the dSLIM family of TLR-9 agonists—with its most
prominent member being MGN1703—constitute a new class
of efficacious immunomodulatory molecules free from any
chemical modifications. In fact, MGN1703 has shown a good
safety profile in a phase 1 clinical trial in patients with solid
tumors [61]. Furthermore, it is currently being evaluated in
clinical trials for the treatment of a variety of cancers. One, a
randomized phase 2 trial in patients with metastatic colo-
rectal carcinoma, has recently been completed and shown
that MGN1703 maintenance treatment after first-line che-
motherapy was well tolerated and appeared to induce durable
and prolonged progression free survival and disease control
in a subgroup of patients [62].
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